Our goal is the generation of novel vaccines directed against chronic diseases and beyond.
Building on the proprietary WISIT platform technology, we are currently developing such therapeutic neoglucoconjugate vaccines for three indications, with Parkinson’s disease as our lead indication and aggregated aSynuclein as prime target molecule.
Our Pipeline
*… POC/Preclinical includes in vivo Proof of Concept and preclinical development required for IND filing
(1)… entry of the lead candidate for PD into Phase 1 clinical testing is expected for Q2/2024
(1)… entry of the lead candidate for PD into Phase 1 clinical testing is expected for Q2/2024
